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Abstract 25 
Objective: Beneficial effects of adrenalectomy on cardiovascular risk factors in patients with Subclinical 26 
Cushing Syndrome (SCS) are uncertain. We sought to conduct a systematic review and meta-analysis 27 
with the following objectives: 1) determine the effect of adrenalectomy compared to conservative 28 
management on cardiovascular risk factors in patients with SCS and 2) compare the effect of 29 
adrenalectomy on cardiovascular risk factors in patients with SCS versus those with a non-functioning 30 
(NF) adrenal tumor. 31 
Methods: Medline In-Process & Other Non-Indexed Citations, MEDLINE, EMBASE, and Cochrane 32 
Central Register of Controlled Trial were searched on November 17th, 2015. Reviewers extracted data and 33 
assessed methodological quality in duplicate. 34 
Results: We included 26 studies reporting on 584 patients with SCS and 457 patients with NF adrenal 35 
tumors. Studies used different definitions of SCS. Patients with SCS undergoing adrenalectomy 36 
demonstrated an overall improvement in cardiovascular risk factors (61% for hypertension, 52% for 37 
diabetes mellitus, 45% for obesity and 24% for dyslipidemia). When compared to conservative 38 
management, patients with SCS undergoing adrenalectomy experienced improvement in hypertension 39 
(RR 11, 95% CI 4.3 - 27.8) and diabetes mellitus (RR 3.9, 95%CI 1.5- 9.9), but not dyslipidemia (RR 2.6, 40 
95%CI 0.97 -7.2) or obesity (RR 3.4 (95%CI 0.95-12)). Patients with NF adrenal tumors experienced 41 
improvement in hypertension (21/54 patients), however, insufficient data exist for comparison to patients 42 
with SCS. 43 
Conclusions: Available low to moderate quality evidence from heterogeneous studies suggests a 44 
beneficial effect of adrenalectomy on cardiovascular risk factors in patients with SCS overall and as 45 




Subclinical Cushing syndrome (SCS) is a controversial disorder in name, definition, and management 1-6 50 
but is currently diagnosed in at least a third of patients with incidentally discovered adrenal masses7, 8 and 51 
therefore could affect up to 2% of the general population. SCS is most commonly described as the 52 
presence of inappropriate cortisol production as defined by insufficient suppressibility with 53 
dexamethasone and/or subsequent  alterations of the hypothalamic pituitary adrenal (HPA) axis without 54 
classic, clinically overt signs and symptoms of cortisol excess, such as proximal myopathy, striae, adipose 55 
redistribution, and cortisol-induced metabolic abnormalities. 9, 10 Numerous definitions have been applied 56 
to characterize  HPA axis alteration, and even when the  same diagnostic cutoff criteria are used, 57 
interpretation of results is complicated by differences in assay methodology and individual patient factors 58 
such as co-morbid depression and obesity.1 59 
Patients with an adrenal mass associated with SCS present with an increased prevalence of several 60 
cardiovascular risk factors such as hypertension (HTN), diabetes mellitus type 2 (DM2), dyslipidemia, 61 
and obesity.11-13 Previous studies suggest that patients with SCS are at higher risk for developing 62 
cardiovascular events14-16 and experience an increased cardiovascular mortality.17, 18  However, studies 63 
attempting to investigate the beneficial effect of adrenalectomy on cardiovascular risk factors in patients 64 
with SCS are characterized by small sample sizes and have generated inconsistent results. While several 65 
authors reported various degrees of improvement in metabolic parameters 19-21, others showed no 66 
significant metabolic effect of adrenalectomy 22, 23 in patients with autonomous glucocorticoid production.   67 
Moreover, several studies have reported a degree of improvement in cardiovascular risk factors after 68 
adrenalectomy  in patients with so called non-functioning  (NF) adrenal tumors; whether this could be due 69 
to  mild autonomous glucocorticoid production from an adrenal tumor without resultant detectable 70 
abnormality of the HPA axis  or, possibly, an intrinsic effect of adrenalectomy per se is unknown. 11, 19  71 
 72 
Insecurity of diagnosis and unclear surgical benefit to patients with SCS leads to delaying adrenalectomy 73 
until the associated comorbidities develop or progress.  Conversely, certain patients undergo a potentially 74 
unnecessary surgery, as evidenced by the lack of post-surgical adrenal insufficiency in at least a third of 75 
patients with SCS.24  Until the dilemma of SCS is solved, patients risk progression towards a potentially 76 
avoidable clinically significant event (and even premature death) and are exposed to multiple tests and 77 
therapies - all of which likely causing undesirable health and economic consequences. 78 
In order to provide a meaningful understanding of existent data in regards to the beneficial effects of 79 
adrenalectomy on cardiovascular risk factors in patients with SCS, we sought to conduct a systematic 80 
review and meta-analysis with the following objectives: 1) determine the effect of adrenalectomy 81 
compared to conservative management on cardiovascular risk factors in patients with SCS and 2) 82 
compare the effect of adrenalectomy on cardiovascular risk factors in patients with SCS versus those with 83 
a NF adrenal tumor. 84 
Methods and Evidence Acquisition 85 
This study was performed based on a protocol that was designed in advance. The results of this review are 86 
reported according to the PRISMA statement (Preferred reporting items for systematic reviews and meta-87 
analyses)25. We included studies that evaluated adrenalectomy alone or in comparison to other 88 
interventions, for the treatment of SCS and/or NF adrenal tumors. 89 
Inclusion and exclusion criteria 90 
The inclusion criteria were specified in the predefined protocol to include original prospective and 91 
retrospective comparative and non-comparative studies that enrolled adults with either NF adrenal tumors  92 
or adrenal tumors with SCS (as defined by authors), with at least 5 patients undergoing adrenalectomy, 93 
and reported outcomes of interest before and after adrenalectomy. We included studies regardless of their 94 
publication status or language. We excluded all non-original studies and case reports.  Dichotomous 95 
outcomes of interest were:  hypertension, pre-diabetes or diabetes mellitus, obesity and dyslipidemia. 96 
Continuous outcomes were:  systolic and diastolic blood pressure, body mass index (BMI), weight, 97 
fasting glucose concentrations, glycosylated hemoglobin (HbA1c), total cholesterol, triglycerides, high 98 
density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol. 99 
Data Sources and Search Strategy 100 
A comprehensive search of several databases was conducted from each database’s earliest inception to 101 
November 17, 2015, in any language and in adults. The databases included Ovid Medline In-Process & 102 
Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of 103 
Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy 104 
(Suppl. Table 1) was designed and conducted by an experienced librarian with input from the study’s 105 
principal investigator. Controlled vocabulary supplemented with keywords was used to search for 106 
comparative studies of surgery in patients with adrenal tumors.  107 
Selection of Studies 108 
Initial screening of the identified studies was performed by five independent reviewers (all 109 
endocrinologists with adrenal expertise). Titles and abstracts of the identified studies were screened in 110 
duplicate, taking into consideration the pre-defined inclusion criteria. Many of the identified studies 111 
retrieved by our search were non-relevant or non-original and were excluded at this phase. Full-text 112 
screening was then performed in duplicate to assess eligibility for final inclusion and discrepancies were 113 
resolved through discussion and consensus. 114 
Data extraction 115 
Reviewers extracted data independently from the included studies in duplicate, using a standardized, 116 
piloted, web-based form that was developed based on the protocol. Data extracted included: 117 
demographics of participants, patient inclusion criteria, study design, intervention details, and outcomes 118 
of interest. Any disagreements or differences in extracted data were resolved by consensus or referral to 119 
the full text of the study. 120 
Methodological quality and risk of bias assessment 121 
The quality of each study was assessed in duplicate. Observational studies were evaluated using the 122 
Newcastle-Ottawa tool which included assessment of the following (i) how the sample represented the 123 
population of interest, (ii) how the comparative group was selected, (iii) how the outcome was assessed, 124 
and (iv) the length and adequacy of follow-up when applicable.  Randomized trials were evaluated 125 
independently by the authors using the Cochrane Risk of Bias assessment tool. 126 
Statistical analysis 127 
We conducted a meta-analysis using the random-effect model to pool estimates from the included studies. 128 
A random-effect model was used, rather than a fixed-effects model, in order to account for heterogeneity 129 
between studies as well as within-study variability. We used the I2 statistic to estimate the percentage of 130 
total between-study variation due to heterogeneity rather than chance (ranging from 0% to 100%).26 I-131 
square values of 25%, 50%, and 75% are thought to represent low, moderate, and high heterogeneity, 132 
respectively. Statistical analyses were conducted through OpenMeta[Analyst].26-28 All values were two-133 
tailed and P < .05 was set as the threshold for statistical significance.   134 
To assess whether the benefit of adrenalectomy was influenced by the definition of SCS, a subgroup 135 
analysis was performed in 3 subgroups of patients stratified based on the dexamethasone suppression test 136 
(DST) cortisol cutoff (the most common variable used). Subgroup 1 included studies in which the DST 137 
cortisol cutoff was ≥ 3 µg/dL, 83 nmol/L  (13 studies, DST cortisol cutoff  3-5  µg/dL, 83-138 nmol/L); 138 
subgroup 2 included studies using a cortisol cutoff of <3  µg/dL, 83 nmol/L (8 studies, DST cortisol 139 
cutoff 1-2.5  µg/dL, 28-69 nmol/L); and subgroup 3 comprised studies that either did not report a DST 140 
cortisol cutoff or did not provide how SCS was defined (5 studies). We selected to perform a subgroup 141 
analysis only for outcomes reported for at least 25 patients in each subgroup (HTN and DM2). 142 
Results 143 
Characteristics of included studies 144 
The search yielded 854 references for abstract screening of which 26 studies19-23, 29-49 were included in this 145 
systematic review (Figure 1). Eligible studies included 25 cohort studies (16 retrospective and 9 146 
prospective studies) and one randomized controlled trial. Studies were mostly from European (n=15) or 147 
Asian centers (n=9), and 2 were USA-based (Table 1). A total of 584 patients with SCS (mean age 56 yrs, 148 
66.8% women) and 457 patients with NF adrenal tumors (mean age 54.9 yrs, 61.5% women) were 149 
included.  Patients with SCS presented with high prevalence of cardiovascular risk factors (HTN (68%), 150 
DM2 (30%), dyslipidemia (25.6%), and obesity (34.6%)).  In patients with NF adrenal tumors, prevalence 151 
of HTN was 48.4%, DM2 - 8.2%, dyslipidemia - 22.1%, and obesity - 18.8%. 152 
Authors reported on various outcome improvements in patients with SCS before and after adrenalectomy 153 
in 24 studies; however only 10 studies provided comparative data for patients with SCS managed 154 
conservatively (Table 1).  In 6 studies, authors compared the effect of adrenalectomy on outcomes in both 155 
SCS and NF adrenal tumor groups. In 3 studies, the effect of adrenalectomy on metabolic parameters in 156 
patients with NF was compared to conservative management. 157 
As expected, studies used different definitions of SCS (Table 2). Definitions of selected clinical outcomes 158 
also varied, as did the definition of outcome “improvement” (Table 3).  All patients had assessment at 159 
baseline and after either adrenalectomy or a period of conservative management. Most studies reassessed 160 
patients at least 6 months after the surgery (n=17, Table 3) with a median follow up of 28 (1-109) months 161 
(median or mean follow up was reported only in 11 studies). 162 
Metabolic outcome in patients with SCS comparing before and after adrenalectomy 163 
Patients with SCS undergoing adrenalectomy demonstrated an overall improvement in cardiovascular risk 164 
factors (Table 4). Improvement in hypertension was observed in 60.5% of patients with SCS; systolic 165 
blood pressure decreased by a mean of 12.7 mm Hg (CI95% 7.1-18.3 mmHg) and diastolic blood 166 
pressure decreased by a mean of 9.3 mm Hg (CI 95% 3.85-14.83 mm Hg).  Improvement in DM2 was 167 
observed in 51.5% of patients. Only 3 studies examined the effect of adrenalectomy on fasting blood 168 
glucose and 4 studies reported on HbA1c changes, with mild but significant decreases in both. 169 
Improvement in obesity was observed in 45% of patients.; following adrenalectomy, BMI decreased by a 170 
mean of 1.96 kg/m2 (CI95% 0.59-3.32 kg/m2) after adrenalectomy. Adrenalectomy had the least effect on 171 
dyslipidemia (24% of patients improved). In three studies examining the effect of adrenalectomy on 172 
triglycerides, LDL and HDL cholesterol, no significant changes following adrenalectomy were noted 173 
(Table 4).  174 
Subgroup analysis based on DST cortisol cutoff criteria was performed only for the outcomes of HTN and 175 
DM2. Patients in subgroup 1 (136 with hypertension, 61 with DM2), subgroup 2 (71 with HTN, 34 with 176 
DM2) and subgroup 3 (58 with HTN and 25 with DM2) experienced similar rates of HTN and DM2 177 
improvement following adrenalectomy (Supplemental figure 1 and 2). Subgroup analysis of obesity and 178 
other outcomes was not performed due to small numbers). 179 
Metabolic outcome in patients with SCS comparing adrenalectomy vs conservative management: 180 
Our search identified 10 studies that included both patients who underwent either adrenalectomy (132 181 
patients with SCS) or were  conservatively managed (135 patients with SCS). When compared to 182 
conservative management, patients with SCS undergoing adrenalectomy experienced a statistically 183 
significant improvement in hypertension (RR 11, 95% CI 4.3 - 27.8) and DM2 (RR 3.9, 95%CI 1.5- 9.9), 184 
but not dyslipidemia (RR 2.6, 95%CI 0.97 -7.2) or obesity (RR 3.4 (95%CI 0.95-12)), (Figure 2A). Data 185 
on continuous outcomes derived only from 4 studies demonstrated a significant decrease of systolic blood 186 
pressure (SBP) and diastolic blood pressure (DBP) as well as fasting glucose concentrations in patients 187 
with SCS undergoing adrenalectomy when compared to conservative management.   No significant 188 
change in BMI decrease was noted between groups (Figure 2B).   189 
Patients with NF adrenal tumors: 190 
Metabolic outcome in patients with NF adrenal tumors comparing before and after adrenalectomy 191 
Our search identified 8 studies reporting on clinical outcomes before and after adrenalectomy in patients 192 
with NF adrenal tumors. 19, 31, 34, 35, 37, 39, 47, 48 In 5 of these studies (54 patients with hypertension), 21 193 
patients had improvement of BP control after adrenalectomy (42%, 95%CI 21 to 63%), Supplemental 194 
Figure 3.  In 4 studies, 3/14 and 3/23 patients with DM2 and dyslipidemia respectively improved after 195 
adrenalectomy, Supplemental figure 3.  196 
Metabolic outcome in patients with NF adrenal tumors comparing adrenalectomy vs conservative 197 
management 198 
In 2 studies, metabolic outcomes of adrenalectomy was compared with conservative management.19, 48  199 
Meta-analysis was not performed due to small numbers and studies are discussed individually. When 200 
compared to conservative management, the adrenalectomy effect on hypertension was variable among the 201 
studies.  In the study by Chiodini et al, a statistically significant improvement of  systolic blood pressure 202 
was found between surgical and non-surgical NF groups (9/30 versus 5/37, P=0.05).19 However, in a 203 
larger study by Sereg et al., no differences were found when the prevalence of cardiovascular events, 204 
hypertension, obesity, dyslipidemia and DM2 in patients with surgically treated NF adrenal tumors was 205 
compared to patients with NF adrenal tumors followed conservatively. Patients also had similar BMIs, 206 
cholesterol concentrations and glucose concentrations at follow up assessment.48  207 
Metabolic outcome comparing adrenalectomy in patients with SCS versus patients with NF adrenal 208 
tumors  209 
Only 6 studies aimed to compare the effect of adrenalectomy on comorbidities in both SCS and NF 210 
populations.19, 31, 35, 37, 39, 47 Taking into consideration the small sample size, we did not find statistically 211 
significant differences between patients with SCS vs. NF adrenal tumors with regard to impact of 212 
adrenalectomy  on HTN (39 SCS and 43 NF patients), DM2 (19 SCS and 14 NF patients), obesity (16 213 
SCS and 14 NF patients) and dyslipidemia (22 SCS and 23 NF patients) (data not shown). There were 214 
insufficient data to evaluate any difference between patients with SCS vs. patients with NF adrenal 215 
tumors on any continuous outcomes. 216 
The largest comparative study of both surgical and non-surgical patients with SCS and NF adrenal tumors 217 
contained only 16 to 37 patients in each arm.19 In this study, surgical patients with SCS experienced 218 
greater improvements in several outcomes when compared to surgically treated patients with NF adrenal 219 
tumors, including more weight loss after surgery (32% vs 10%), improved BP (56% vs 30%) and 220 
improved fasting glucose concentrations (48% vs 10%).19 In a smaller study, more than half of the 13 221 
patients with NF adrenal tumors treated with adrenalectomy experienced improvements in BP and DM2 222 
control. However, it is important to mention that 4 patients developed postoperative temporary adrenal 223 
insufficiency, raising the question of whether these patients were misclassified as having a NF adrenal 224 
mass.47  225 
Risk of bias assessment 226 
Except for one randomized controlled trial, all of the studies were observational. The observational 227 
studies were of moderate risk of bias. Samples were not representative enough in most studies. Most of 228 
the included studies had good ascertainment of the exposure but not of the outcome. Additionally, many 229 
studies were judged to lack a period of sufficient length of follow up for the change in outcome to occur.  230 
Discussion 231 
This systematic review and meta-analysis summarizes the available evidence of adrenalectomy effects on 232 
cardiovascular risk factors in patients with SCS.  Based on the limited and heterogeneous published data, 233 
we demonstrate that a significant proportion of patients with SCS improve their cardiovascular 234 
morbidities (HTN, DM2, dyslipidemia, and obesity) after adrenalectomy. The beneficial effect of 235 
adrenalectomy persists for HTN and DM2 in the comparative analysis of patients with SCS treated with 236 
adrenalectomy versus conservative management.  Notably, the stringency of SCS criteria varied between 237 
the studies. Despite the fact that subgroup analysis has not shown higher benefit of adrenalectomy in 238 
patients with a DST cortisol of  ≥3 µg/dL, the number of patients in each subgroup was small and could 239 
have accounted for the absence of significant differences in the benefit of adrenalectomy in relation to the 240 
SCS definition used.  241 
Interestingly, we have also found that a proportion of patients with NF adrenal tumors experienced an 242 
improvement of HTN after adrenalectomy. One of the likely explanations for this observation could be a 243 
potential misclassification of patients; for example, one study described that a significant proportion of 244 
patients with NF adrenal tumors developed adrenal insufficiency after surgery, clearly suggesting that 245 
glucocorticoid autonomous production was not recognized preoperatively.47 Overall glucocorticoid 246 
production has been linked to HTN, abnormal glucose tolerance and increased BMI.50  Thus, it is also 247 
possible that a temporary reduction of the overall glucocorticoid load caused by unilateral adrenalectomy 248 
could have contributed to a short-term BP improvement described in patients with NF adrenal tumors.  249 
Limitations and strengths 250 
The strengths of this review include an in-depth and comprehensive literature search, a focused review 251 
question, and predefined group and subgroup analyses. Our review includes mainly retrospective cohort 252 
studies of small sample size. Our results are limited by the heterogeneous definitions of SCS. One may 253 
dispute the legitimacy of combining patients diagnosed with SCS using different criteria. However, 254 
comparative analysis showed similar improvement in most cardiovascular factors. Moreover, we have 255 
performed a subgroup analysis using different DST cortisol cutoffs. In contrast to our expectations to find 256 
more benefit in the higher DST cortisol cutoff subgroup, no significantly different outcomes from the 257 
overall analysis were noted. Various SCS definitions used in the included studies brings to surface the 258 
still-ongoing debate on the best diagnostic cutoffs for diagnosing SCS. Even when the same definition of 259 
SCS is used across the studies, differences in assay methods and presence of individual factors 260 
contributing to possible false positive or negative results51 may lead to subsequent misclassification of 261 
patients.40, 47 Most clinicians do not rely solely on the results of biochemical cutoffs to make a diagnosis, 262 
but also on clinical suspicion and existence of comorbidities.   263 
A significant limitation of this review stems from the significant differences in how and when the 264 
outcomes of interest were assessed (Table 3).  Inconsistent definitions of comorbidities as well as degrees 265 
of improvement, in many cases applied retrospectively, limit our ability to provide accurate estimates of 266 
the benefits resulting from adrenalectomy. It was also unclear how aggressive the conservative 267 
management was in non-surgical patients and what factors influenced the decision not to undergo 268 
adrenalectomy, with all but one study not applying randomization. In addition, we were not able to 269 
perform any analysis of age, gender and tumor size influence on cardiovascular outcomes as these 270 
variable were inconsistently reported separately for each subgroup of patients.  271 
Comparison with previous studies 272 
To our knowledge, only one previous systematic review of the literature assessed the effect of 273 
adrenalectomy in patients with SCS.52  Iacobone et al limited their review of studies to those published in 274 
English consisting of at least 10 operated patients, and only including  patients with SCS. They identified 275 
only 7 publications, which are also reviewed in our work. Our current systematic review provides 276 
additional value by including smaller cohort studies, as well as studies published in languages other than 277 
English (n=2)  allowing for a larger total cohort size. Our current review also includes comparative NF 278 
adrenal tumor studies.  279 
Review implications 280 
This review raises several important questions needing further clarification. The first question mirrors the 281 
ongoing debate on the best SCS definition. The overnight 1-mg DST is most consistently used among the 282 
included studies; however, the best cutoff distinguishing patients with clinically relevant autonomous 283 
glucocorticoid production is still undetermined. It could be useful to adopt a retrospective approach and 284 
examine only patients with SCS who indeed experienced a predefined degree of improvement in their 285 
comorbidities with adrenalectomy to gain more insight, however, this was technically not feasible to 286 
perform in the current review. Secondly, conservative management differs in its intensity among the 287 
studies included. Data from a well-designed randomized controlled trial comparing adrenalectomy to 288 
aggressive management of HTN, DM2 and obesity in patients with SCS is needed. Thirdly, it is unclear 289 
whether the improvement in cardiovascular risk factors noted after adrenalectomy in patients with SCS 290 
actually persisted (or influenced cardiovascular outcomes and mortality) as most studies had short follow 291 
up. Nevertheless, despite many unanswered questions, and bearing in mind the heterogeneity of SCS and 292 
outcome definitions, the findings from our review demonstrate improvement of cardiovascular risk 293 
factors with adrenalectomy in comparison to conservative management in patients with SCS. Until more 294 
data are available, the potential favorable impact of adrenalectomy in patients with SCS should be 295 
discussed with the patient in the context of informed medical decision making. 296 
 Conclusions 297 
Available low to moderate quality evidence derived from heterogeneous studies , most with at least 6 298 
months follow up, suggests a beneficial effect of adrenalectomy on cardiovascular risk factors in patients 299 
with SCS overall and as compared to conservative management. 300 
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